latest news releases from the newsroom
Humphries Appointed Senior Vice President of Canadian Foodservice Operations
HOUSTON, Feb. 15, 2007 (PRIME NEWSWIRE) -- SYSCO Corporation (NYSE:SYY), North America's largest foodservice marketer and distributor, announced today that G. Kent Humphries has been named senior vice president of Canadian foodservice operations. Mr. Humphries has served most recently as president and chief executive officer of Sysco Food Services of Baltimore, LLC and will assume his new position effective March 1, 2007. Mr. Humphries will be responsible for all of SYSCO's broadline foodservice operations in Canada. He succeeds Bruce L. Soltis who will retire at the end of this fiscal year.
Aftersoft Group, Inc.
Aftersoft Group Reports Fiscal Second Quarter Financial Results
NEW YORK and LONDON, Feb. 15, 2007 (PRIME NEWSWIRE) -- Aftersoft Group Inc. ("Aftersoft") (OTCBB:ASFG), a leading supplier of software and services to the automotive aftermarket in the U.S., UK and Canada, today announced the results of operations for fiscal second quarter ended December 31, 2006. Revenues for the second quarter were $6.8 million compared to $4.8 million for the second quarter of the prior fiscal year, an increase of 30%. The Company reported net income of $996,000 versus $488,000 for the comparable period in previous fiscal year, an increase of 104%.
Industrial Distribution Group, Inc.
Industrial Distribution Group, Inc. Announces Date for Fourth Quarter and Full-Year 2006 Earnings Conference Call and Webcast
ATLANTA, Feb. 15, 2007 (PRIME NEWSWIRE) -- Industrial Distribution Group, Inc. (Nasdaq:IDGR) will host a conference call and live webcast on Thursday, February 22, 2007 to discuss its fourth quarter and full-year 2006 results, provide a strategy update, and the Company's outlook for full-year 2007, which will be announced before the opening of the market.
Timberline Resources Corporation
Timberline Reports $3.21 Million in Quarterly Revenue
COEUR DALENE, Idaho, Feb. 15, 2007 (PRIME NEWSWIRE) -- Timberline Resources Corporation ("Timberline") (OTCBB:TBLC) today announced financial results for its fiscal first quarter, reporting record revenues of $3.21 million. Virtually all revenue was generated by Timberline's contract drilling subsidiary, Kettle Drilling, Inc. ("Kettle"), including Kettle's Mexican subsidiary, World Wide Exploration, S.A. de C.V. ("World Wide"). Net of business investments, exploration work, and financing activities, Timberline reported a first quarter loss of $1.14 million.
JetBlue Airways Corporation
JetBlue Customers Booked to Travel Through Monday, Feb. 19 May Rebook Without Penalty through Tuesday, May 22, or Convert Value to Apply Toward Future JetBlue Travel
NEW YORK, Feb. 15, 2007 (PRIME NEWSWIRE) -- Customers booked to travel on JetBlue through Monday, Feb. 19, 2007 may voluntarily rebook their travel without penalty or fare difference through Tuesday, May 22, 2007. To rebook, customers are asked to call JetBlue at 800-JETBLUE (800-538-2583). Due to heavy call volume, customers may contact JetBlue anytime through Monday to rebook their travel.
Alteon's Alagebrium Demonstrates Cardiovascular Activity In Recently Published Report Indicating Potential Wide-Ranging Benefits In Cardiovascular Diseases
PARSIPPANY, N.J., February 15, 2007 (PRIME NEWSWIRE) -- Alteon Inc. (AMEX:ALT) announced today that data demonstrating the ability of its compound, alagebrium, to augment flow-mediated dilation (FMD) is the subject of a paper published in the March 2007, Volume 25, No. 3 issue of the Journal of Hypertension, by Susan Zieman, M.D, Ph.D., Assistant Professor, Department of Medicine (Cardiology), and colleagues from Johns Hopkins School of Medicine. The paper, describing an investigator-sponsored Phase 2 clinical trial, indicates that alagebrium can induce changes in flow-mediated dilation and a variety of biomarkers related to inflammation, matrix turnover and endothelial function. The Company believes that this pragmatic demonstration of alagebrium's biological activity in human clinical subjects using a collection of well-validated biomarkers, is supportive of the Company's plans to advance alagebrium's development in cardiac and vascular mediated disease.